“In our latest podcast episode, Dr. Chris Cutie of Johnson and Johnson Innovation covers many questions about the gemcitabine-eluting pretzel, like its origin, catheter changes, assessing toxicity, the SunRISe series, and TAR-200 combo agents.”
Christopher Cutie is the Vice President and Disease Area Leader of Bladder Cancer at The Janssen Pharmaceutical Companies of Johnson & Johnson. He also co – founded Jointpoint and was the chief medical officer at TARIS Bio (acquired by Janssen Oncology).